Samad Abdus, Sultana Y, Aqil M
Department of Pharmaceutics, Faculty of Pharmacy, Jamia Hamdard, New Delhi 110062, India.
Curr Drug Deliv. 2007 Oct;4(4):297-305. doi: 10.2174/156720107782151269.
The discovery of liposome or lipid vesicle emerged from self forming enclosed lipid bi-layer upon hydration; liposome drug delivery systems have played a significant role in formulation of potent drug to improve therapeutics. Recently the liposome formulations are targeted to reduce toxicity and increase accumulation at the target site. There are several new methods of liposome preparation based on lipid drug interaction and liposome disposition mechanism including the inhibition of rapid clearance of liposome by controlling particle size, charge and surface hydration. Most clinical applications of liposomal drug delivery are targeting to tissue with or without expression of target recognition molecules on lipid membrane. The liposomes are characterized with respect to physical, chemical and biological parameters. The sizing of liposome is also critical parameter which helps characterize the liposome which is usually performed by sequential extrusion at relatively low pressure through polycarbonate membrane (PCM). This mode of drug delivery lends more safety and efficacy to administration of several classes of drugs like antiviral, antifungal, antimicrobial, vaccines, anti-tubercular drugs and gene therapeutics. Present applications of the liposomes are in the immunology, dermatology, vaccine adjuvant, eye disorders, brain targeting, infective disease and in tumour therapy. The new developments in this field are the specific binding properties of a drug-carrying liposome to a target cell such as a tumor cell and specific molecules in the body (antibodies, proteins, peptides etc.); stealth liposomes which are especially being used as carriers for hydrophilic (water soluble) anticancer drugs like doxorubicin, mitoxantrone; and bisphosphonate-liposome mediated depletion of macrophages. This review would be a help to the researchers working in the area of liposomal drug delivery.
脂质体或脂质囊泡的发现源于水合后自组装形成的封闭脂质双层;脂质体药物递送系统在强效药物制剂以改善治疗效果方面发挥了重要作用。最近,脂质体制剂旨在降低毒性并增加在靶部位的蓄积。基于脂质-药物相互作用和脂质体处置机制,有几种制备脂质体的新方法,包括通过控制粒径、电荷和表面水合作用来抑制脂质体的快速清除。脂质体药物递送的大多数临床应用靶向脂质膜上有或无靶标识别分子表达的组织。脂质体根据物理、化学和生物学参数进行表征。脂质体的大小也是一个关键参数,有助于表征脂质体,通常通过在相对低压下通过聚碳酸酯膜(PCM)进行连续挤压来实现。这种药物递送方式为几类药物(如抗病毒、抗真菌、抗菌、疫苗、抗结核药物和基因治疗药物)的给药带来了更高的安全性和有效性。脂质体目前的应用领域包括免疫学、皮肤病学、疫苗佐剂、眼部疾病、脑靶向、传染病和肿瘤治疗。该领域的新进展包括载药脂质体与靶细胞(如肿瘤细胞)以及体内特定分子(抗体、蛋白质、肽等)的特异性结合特性;隐形脂质体,尤其用作阿霉素、米托蒽醌等亲水性(水溶性)抗癌药物的载体;以及双膦酸盐脂质体介导的巨噬细胞耗竭。这篇综述将对从事脂质体药物递送领域研究的人员有所帮助。